Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Print
Neal Chawla, MD
Sarcoma Oncology Center
Poster(s):
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
